文献速递妇科

铂敏感复发卵巢癌≥3线化疗的预测因素:GCIG症状受益研究

Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS).
PubMed 文献 · Gynecol Oncol · 2019-12-10

该研究纳入378例铂敏感复发卵巢癌且开始≥3线化疗的女性,评估基线健康相关生活质量(HRQL)和临床病理因素与PFS、OS及早期停止化疗的关联。中位OS为16.6个月,中位PFS为5.3个月;12%早期停止化疗,其中位OS为3.4个月(95%CI: 1.7-7.2)。基线HRQL可预测PFS和OS,结合临床病理因素有助于临床决策。

要点

  • 基线HRQL(如社会功能)与PFS显著相关,调整临床病理因素后仍显著(p=0.03)。
  • 基线PF、RF、SF和GHS是多变量模型中OS的显著预测因素(p<0.007)。
  • 12%患者早期停止化疗,其中位OS仅3.4个月(95%CI: 1.7-7.2)。

核心结论

  • 基线HRQL测量简单,可预测PFS和OS,结合临床病理预后因素可辅助铂敏感复发卵巢癌≥3线化疗的临床决策和治疗推荐。

研究设计与样本

  • GCIG症状受益研究,纳入378例铂敏感复发卵巢癌(无铂间期>6个月)开始≥3线化疗的女性,使用EORTC QLQ-C30/QLQ-OV28评估HRQL,采用Cox回归和logistic回归分析。

主要发现

  • 中位OS为16.6个月,中位PFS为5.3个月;45/378例(12%)早期停止化疗,其中位OS为3.4个月(95%CI: 1.7-7.2)。
  • PF、RF、CF、SF、GHS和AGIS是PFS的显著单变量预测因素(p<0.030);调整临床病理因素后SF仍显著(p=0.03)。
  • PF、RF、CF、SF、GHS和AGIS是OS的显著单变量预测因素(p<0.007);多变量模型中PF、RF、SF和GHS仍显著(p<0.007)。
  • 基线PF和GHS差是早期停止化疗的显著单变量预测因素(p<0.007),但调整临床病理因素后均不显著。

临床怎么用

  • 基线HRQL可与临床病理预后因素联合用于铂敏感复发卵巢癌≥3线化疗患者的临床决策和治疗推荐。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Potentially platinum sensitive recurrent ovarian cancer (PPS ROC) is defined by a platinum-free interval of >6 months, and usually treated with platinum-based chemotherapy with variable response and benefit in women who have had 3 or more lines of chemotherapy(≥3). We identified baseline characteristics (health-related quality of life[HRQL] and clinicopathological factors), associated with PFS, OS and early progression (within 8 weeks). The goal is to improve patient selection for chemotherapy based on a nomogram predicting PFS. METHODS: HRQL was assessed with EORTC QLQ-C30/QLQ-OV28. Associations with PFS and OS were assessed with Cox proportional hazards regression. Variables significant in univariable analysis were included in multivariable analyses using backward elimination to select those significant. Associations with stopping chemotherapy early were assessed with logistic regression. RESULTS: 378 women were enrolled, with median(m)OS and PFS of 16.6 months and 5.3 months, respectively. The majority had ECOGPS 0-1. Chemotherapy was stopped early in 45/378 participants (12%); with mOS 3.4 months (95% CI: 1.7-7.2). Physical function(PF), role function(RF), cognitive function(CF), social function(SF), Global Health Status(GHS) and abdominal/GI symptoms(AGIS) were significant univariable predictors of PFS(p < 0.030). SF remained significant after adjusting for clinicopathological factors; p = 0.03. PF, RF, CF, SF, GHS and AGIS were significant univariable predictors of OS (p < 0.007); PF, RF, SF and GHS remained significant predictors of OS in multivariable models; p < 0.007. Poor baseline PF and GHS were significant univariable predictors of stopping chemotherapy early (p < 0.007) but neither remained significant after adjusting for clinicopathological factors. CONCLUSION: Baseline HRQL is simple to measure, is predictive of PFS and OS and when used in conjunction with clinicopathological prognostic factors, can assist with clinical decision making and treatment recommendations for women with PPSROC≥3.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Roncolato FT, O'Connell RL, Joly F, et al. Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS). Gynecol Oncol. 2019. PMID: 31836184. doi:10.1016/j.ygyno.2019.10.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。